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We measured T-cell responses to human immunodeficiency virus type 1 (HIV-1) cryptic epitopes encoded by
regions of the viral genome not normally translated into viral proteins. T-cell responses to cryptic epitopes and
to regions normally spliced out of the HIV-1 viral proteins Rev and Tat were detected in HIV-1-infected
subjects.
The immune system responds to invading pathogens by rec-
ognizing pathogen-derived peptides. A retrovirus such as hu-
man immunodeficiency virus type 1 (HIV-1) utilizes host cel-
lular machinery for synthesis of viral proteins, and an infected
cell will present proteasomal cleavage products commonly de-
rived from the breakdown products of the main viral proteins.
During protein processing, translational errors can result in
bypassing of the main viral protein reading frames, resulting in
the production of alternate reading frame or cryptic peptide
epitopes (1, 2). Additionally, in the presence of certain cyto-
kines, such as gamma interferon, the composition and function
of the proteosome are altered, with resulting changes in the
processing of epitopes (4). T-cell responses to the protein
products of alternate reading frames can also be induced
through vaccination (11).
The functional role of T-cell responses to cryptic epitopes in
an experimental model of retroviral disease control has re-
cently been established (5), and an epitope from HIV-1 that
was derived from an alternate reading frame has also previ-
ously been described (3). Although most HIV-1 structural viral
proteins are produced from a single, continuous open reading
frame, a subset of the accessory proteins are produced from
spatially separated regions of the genome. In these accessory
proteins, failure of the normal processes of splicing introduces
additional regions of peptide-coding sequence into the mRNA.
These regions have been shown to generate immune responses
in primates infected with simian immunodeficiency virus (9).
We used in silico T-cell immunogenicity prediction methods
to identify peptide epitopes for the HLA-B58, A2, and B7
superfamilies within alternate reading frames in HIV-1 (7). We
measured T-cell responses of HIV-1-positive individuals with
good immunological control of HIV-1 viral load (controllers),
individuals on highly active antiretroviral therapy (HAART)
(HAART-suppressed individuals), and untreated individuals
with uncontrolled HIV-1 viral loads (noncontrollers).
Candidate peptides were selected from the HIV-1 genome
by analyzing the HXB-2 DNA sequence. Open reading frames
that did not correspond to known protein-coding regions of the
HIV-1 genome were identified in the sense direction. Anti-
sense open reading frames were also identified. Alternative
splice sites were identified upstream of the main splice sites for
the Tat and Rev proteins. A graphical representation of
epitope sources is shown in Fig. 1A.
Peptides were identified within these open reading frames with
NetCTL 1.2 software (http://www.cbs.dtu.dk/services/NetCTL/).
Top-scoring epitopes for the HLA-B58, A2, and B7 supertypes
were selected for peptide synthesis. The entire regions of amino
acids resulting from the use of alternate splice sites in Rev and Tat
were synthesized as 9- and 10-mer peptides, respectively. Eight
peptides in total were synthesized and tested in a pool or on an
individual basis.
Sixty-six HIV-1-infected adults were selected for this study.
We focused on a subset of individuals who were able to main-
tain low to undetectable levels of HIV-1 in the absence of any
therapy (“controllers,” with fewer than 5,000 copies/ml HIV-1
plasma viral load without HAART therapy). As a comparison
group, we studied 24 individuals who had higher levels of
viremia (“noncontrollers”). Finally, we studied 20 HAART-
treated individuals with undetectable plasma HIV-1 RNA lev-
els (“HAART-suppressed” individuals).
Peptides were tested in a gamma interferon enzyme-linked
immunospot assay by using cryopreserved peripheral blood
mononuclear cells (PBMC) (10). Cryptic-peptide-specific re-
sponses were assessed for 22 controllers (median CD4 T-cell
count, 629; median HIV RNA level, 299 copies/ml), 24 non-
controllers (median CD4 T-cell count, 282; median plasma
HIV RNA level, 50,625 copies/ml), 20 HAART-suppressed
individuals (median CD4 T-cell count, 580; median plasma
HIV RNA level, 50 copies/ml), and 35 HIV-1-negative low-
risk volunteers.
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No HIV-1-negative volunteer had responses to the pool
of HIV-1 cryptic epitope peptides (data not shown). A total of
11/66 HIV-1 positive subjects had responses to the pool of
cryptic epitope peptides (50 spot-forming units [SFU]/106
PBMC) (Fig. 1B). The noncontrollers had the lowest median
T-cell response to the cryptic peptide pool, and this was sta-
tistically lower than the level for the HAART-suppressed
group and trended to be lower than that for the controllers.
PBMC from these subjects were then tested with individual
peptides which made up the pool (Table 1). Ten subjects made
responses to the Rev- or Tat-derived peptides, and one made
responses to other cryptic peptides (Table 1). One controller
(subject 1133; HLA-A3,31,B57) had a particularly robust re-
sponse of 305 SFU/106 PBMC to the Rev alternate splice site
peptide (Table 1) and also made a response to the Tat-derived
peptide (Table 1). In total, 10/11 patients made responses to
the alternate splice site peptides (Table 1). These are the first
alternate splice site peptide epitopes recognized in humans
infected with HIV-1. It is intriguing to note that the noncon-
trollers had the lowest-magnitude responses to the cryptic pep-
tides, although we cannot tell whether they might have less
control of viremia, because they never made cryptic responses
or their lack of control led to a failure of cytotoxic T lympho-
cyte responses to these epitopes.
The HIV-1 accessory proteins Rev and Tat are each pro-
duced via the removal of what is effectively an intron sequence
in the envelope region of the genome, followed by the joining
of two exons coding for the two parts of the functional protein.
There is a preferred target splice site for the proper joining of
the two component exons into a single functional protein (12).
Alternate splice sites also exist upstream of the target splice
acceptor site for both the Tat and Rev proteins (6). Use of
these alternative splice sites would result in the addition of
novel amino acids encoded upstream of the main splice sites
for the Tat and Rev mRNA. When the aberrantly spliced
mRNA is translated, additional amino acids encoded in the
upstream regions of RNA would be included in the protein. It
is in this region where immunogenic peptides have been iden-
tified in primates (9). Although the peptides that we selected
from HIV-1 do not have high levels of sequence homology to
the simian immunodeficiency virus sequence, they are located
within functionally equivalent areas of the two genomes.
T-cell responses to cryptic epitopes could aid in the control
of HIV-1 replication. It is unclear how much variability within
these regions can be tolerated in a functional viral genome.
Mutations resulting in the loss of the upstream splice site in the
Tat or Rev reading frame could adversely affect Env gene
function, and the reduced functionality of the Tat or Rev
proteins caused by use of the alternate splice site could lead to
viral latency. As such, responses against splice variant regions
could help to target and eliminate latently infected cells. Fur-
ther study will be needed to investigate the potential of cryptic
epitopes as antigens in a vaccine against HIV-1.
TABLE 1. Positive responses to the cryptic peptide poola
Patient
no.
No. of SFU/million PBMC for:
HXB2-
ORF18-140
(IAFPTFCHM)
HXB2-
ORF19-64
(TSSSARLPF)
REV leader
(RIFTIIVSD)
TAT leader
(SRDIHHYRFR)
720 325
839 130
1133 305 290
1516 105 50
2017 70
2050 60
2056 90 65
2063 55
2089 65
2102 90
3101 230
a For the 11 positive responders to the cryptic peptide pool, responses to the
individual cryptic peptides were tested. Values for responses that were positive
are shown in the table. The amino acid sequence (in amino acid code) is shown
for each of the four cryptic peptides that gave positive responses. No positive
responses to HXB2-ORF14-27 (TSWCSLLYW), HXB2-ORF15-17 (LSSSHSF
PY), HXB2-ORF28-79 (LAYFPVFRF), or HXB2-ORF36-17 (KTSNSPYHF)
were detected.
FIG. 1. (A) Sources of cryptic epitope peptides encoded by the
HIV-1 genome. Candidate cryptic epitope peptides were selected
from three sources, identified by arrows on the figure: alternate
reading frames with Met start codons whose products differed from
the main structural or accessory protein coded by that region of the
genome (arrow 1), antisense reading frames on the strand opposite
from that corresponding to the main structural or accessory protein
coded by that region of the genome (arrow 2), and alternate splice
sites with intervening sequence that code for additional amino acids
potentially added to multiexon proteins coded by the HIV genome
(arrow 3) (8). The dashed lines that precede each downstream
splice site for each protein represent the additional peptide region
incorporated into the proteins by the use of the alternate splice site.
(B) T-cell responses to pools of cryptic epitope antigens as mea-
sured by an enzyme-linked immunospot assay. The study partici-
pants tested were divided into three clinical categories: “control-
lers,” with less than 5,000 copies/ml HIV-1 plasma viral load
without HAART therapy, “HAART-suppressed” individuals, who
were on various regimens of HAART, and “noncontrollers,” with
uncontrolled viral load (not on HAART). The median is shown by
the solid black line and the cutoff threshold of 50 SFU/million cells
drawn with a dotted line across the graph. Statistics were performed
using the Mann-Whitney test.
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